Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: Final results of the National Cancer Research Institute CLL206 Trial

Journal of Clinical Oncology

Volumn 30, Issue 14, 2012, Pages 1647-1655

  Pettitt, Andrew R ^a,b   Jackson, Richard ^a   Carruthers, Stacey ^a   Dodd, James ^a   Dodd, Susanna ^a   Oates, Melanie ^a   Johnson, Gillian G ^b   Schuh, Anna ^c   Matutes, Estella ^d   Dearden, Claire E ^d   Catovsky, Daniel ^d   Radford, John A ^e   Bloor, Adrian ^e   Follows, George A ^f   Devereux, Stephen ^g   Kruger, Anton ⁱ   Blundell, Julie ⁱ   Agrawal, Samir ^h   Allsup, David ^j   Proctor, Stephen ^k   Heartin, Earnest ^l   Oscier, David ^m   Hamblin, Terry J ^k   Rawstron, Andrew ^n,o   Hillmen, Peter ⁿ   more..

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^g KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^h BARTS HEALTH NHS TRUST   (United Kingdom)

ⁱ ROYAL CORNWALL HOSPITALS NHS TRUST   (United Kingdom)

^j HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^k UNIVERSITY OF NEWCASTLE   (Australia)

^l BETSI CADWALADR UNIVERSITY HEALTH BOARD   (United Kingdom)

^m POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

ⁿ LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^o UNIVERSITY OF YORK   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ALLOPURINOL; CHLORAMBUCIL; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; ITRACONAZOLE; LANSOPRAZOLE; METHYLPREDNISOLONE; PREDNISONE; PROTEIN P53; VALGANCICLOVIR; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CANDIDIASIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; COUGHING; CYSTITIS; CYTOMEGALOVIRUS INFECTION; DEEP VEIN THROMBOSIS; DIARRHEA; DISORIENTATION; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DYSPEPSIA; DYSPHAGIA; DYSPNEA; ENCEPHALITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GENE DELETION; HEPATITIS; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOKALEMIA; INFECTION; INFLUENZA; MALE; METABOLIC DISORDER; MORTALITY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; RASH; SEPTICEMIA; SIDE EFFECT; SINUSITIS; SWEAT; TASTE DISORDER; THORAX PAIN; THROMBOCYTOPENIA; TREMOR; URINE RETENTION; ANTIBIOTIC PROPHYLAXIS; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; GENETICS; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; ORGANIZATION; PROPORTIONAL HAZARDS MODEL; REMISSION; RISK ASSESSMENT; STATISTICAL MODEL; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; UNITED KINGDOM;

ACADEMIES AND INSTITUTES; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTIC PROPHYLAXIS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GENE DELETION; GENES, P53; GREAT BRITAIN; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LOGISTIC MODELS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84863769805     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.9695     Document Type: Article

References (50)

1. Chiorazzi N, Rai KR, Ferrarini M: Chronic lymphocytic leukemia. N Engl J Med 352:804-815, 2005
2. Cramer P, Hallek M: Prognostic factors in chronic lymphocytic leukemia-What do we need to know? Nat Rev Clin Oncol 8:38-47, 2011
3. Zenz T, Mertens D, Küppers R, et al: From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 10:37-50, 2010
4. Vousden KH, Prives C: Blinded by the light: The growing complexity of p53. Cell 137:413-431, 2009
5. Hollstein M, Sidransky D, Vogelstein B, et al: p53 mutations in human cancers. Science 253:49-53, 1991
6. Grever MR, Lucas DM, Dewald GW, et al: Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 25: 799-804, 2007
7. Gonzalez D, Martinez P, Wade R, et al: Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: Results from the LRF CLL4 trial. J Clin Oncol 29:2223-2229, 2011
8. Zenz T, Eichhorst B, Busch R, et al: TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 28:4473-4479, 2010
9. Zenz T, Häbe S, Denzel T, et al: Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): Dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 114:2589-2597, 2009
10. Zenz T, Kröber A, Scherer K, et al: Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: Results from a detailed genetic characterization with long-term follow-up. Blood 112:3322-3329, 2008
11. Dicker F, Herholz H, Schnittger S, et al: The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 23:117-124, 2009
12. Rossi D, Cerri M, Deambrogi C, et al: The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: Implications for overall survival and chemorefractoriness. Clin Cancer Res 15:995-1004, 2009
13. Malcikova J, Smardova J, Rocnova L, et al: Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood 114: 5307-5314, 2009
14. Hillmen P, Skotnicki AB, Robak T, et al: Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25:5616-5623, 2007
15. Catovsky D, Richards S, Matutes E, et al: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet 370:230-239, 2007
16. Bosch F, Ferrer A, Villamor N, et al: Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: High response rate and disease eradication. Clin Cancer Res 14:155-161, 2008
17. Byrd JC, Gribben JG, Peterson BL, et al: Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy. J Clin Oncol 24:437-443, 2006
18. Hallek M, Fischer K, Fingerle-Rowson G, et al: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: A randomised, open-label, phase 3 trial. Lancet 376:1164-1174, 2010
19. Bosch F, Abrisqueta P, Villamor N, et al: Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: A new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol 27:4578-4584, 2009
20. Fischer K, Cramer P, Stilgenbauer S, et al: Bendamustine combined with rituximab (BR) in first-Line therapy of advanced CLL: A multicenter phase II trial of the German CLL Study Group (GCLLSG). Blood 114, 2009 (abstr 205)
21. Kay NE, Geyer SM, Call TG, et al: Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109:405-411, 2007
22. Lowe SW, Ruley HE, Jacks T, et al: p53- dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993
23. Clarke AR, Purdie CA, Harrison DJ, et al: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852, 1993
24. Pettitt AR, Clarke AR, Cawley JC, et al: Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms. Br J Haematol 105:986-988, 1999
25. Hale G, Bright S, Chumbley G, et al: Removal of T cells from bone marrow for transplantation: A monoclonal antilymphocyte antibody that fixes human complement. Blood 62:873-882, 1983
26. Osterborg A, Foà R, Bezares RF, et al: Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 23:1980-1988, 2009
27. Keating MJ, Flinn I, Jain V, et al: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood 99:3554-3561, 2002
28. Ferrajoli A, O'Brien SM, Cortes JE, et al: Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 98:773-778, 2003
29. Rai KR, Freter CE, Mercier RJ, et al: Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 20:3891-3897, 2002
30. Moreton P, Kennedy B, Lucas G, et al: Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23:2971-2979, 2005
31. Lundin J, Kimby E, Björkholm M, et al: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100:768-773, 2002
32. Lozanski G, Heerema NA, Flinn IW, et al: Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103:3278-3281, 2004
33. Osuji NC, Del Giudice I, Matutes E, et al: The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica 90:1435-1436, 2005
34. Stilgenbauer S, Zenz T, Winkler D, et al: Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: Clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 27:3994-4001, 2009
35. Thornton PD, Matutes E, Bosanquet AG, et al: High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 82:759-765, 2003
36. Pettitt AR, Matutes E, Oscier D: Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 20:1441-1445, 2006
37. Hallek M, Cheson BD, Catovsky D, et al: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446-5456, 2008
38. Ishioka C, Frebourg T, Yan YX, et al: Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Genet 5:124-129, 1993
39. Castro JE, Sandoval-Sus JD, Bole J, et al: Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 22(11):2048-2053, 2008
40. Dungarwalla M, Evans SO, Riley U, et al: High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica 93(3):475-476, 2008
41. Quinn JP, Mohamedbhai S, Chipperfield K, et al: Efficacy of rituximab in combination with steroids in refractory chronic lymphocytic leukemia. Leuk Lymphoma 49(10):1995-1998, 2008
42. Reference deleted
43. Dreger P, Corradini P, Kimby E, et al: Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: The EBMT transplant consensus. Leukemia 21:12-17, 2007
44. Michallet M, Sobh M, Milligan D, et al: The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: A retrospective study from the EBMT registry. Leukemia 24:1725-1731, 2010
45. Schetelig J, van Biezen A, Brand R, et al: Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: A retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol 26:5094-5100, 2008
46. Dreger P, Döhner H, Ritgen M, et al: Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: Long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 116: 2438-2447, 2010
47. Dreger P: Allotransplantation for chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2009:602-609, 2009
48. Elter T, Molnar I, Kuhlmann J, et al: Pharmacokinetics of alemtuzumab and the relevance in clinical practice. Leuk Lymphoma 49:2256-2262, 2008
49. Hale G, Rebello P, Brettman LR, et al: Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 104:948-955, 2004
50. Stilgenbauer S, Cymbalista F, Leblond V, et al: Subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allo-SCT in CLL with 17p- or refractory to fludarabine- interim analysis of the CLL2O trial of the GCLLSG and FCGCLL/MW. Blood 116, 2010 (abstr 920)